Feed SNN
SN

Smith & Nephew SNN · NYSE

$30.11 -1.18% (-$0.36)

Market cap
$12.6B
Enterprise value
$15.7B
P/E
19.9x
Forward P/E
13.2x
PEG
0.4x
P/S
2.0x
P/FCF
14.8x
EV/EBITDA
11.3x
ROIC
6.8%
Gross margin
68.4%
Net margin
10.1%
Dividend yield
2.64%
Payout ratio
52.4%
Net debt/EBITDA
2.2x
Beta
0.69
Free float
99.0%

About the company

Smith & Nephew plc (SN) is a British company specializing in the manufacture and distribution of healthcare devices and surgical products. Their portfolio includes a wide range of products in the fields of orthopedics, sports medicine, joint surgery, traumatology, and advanced surgical technologies. The company manufactures and supplies implants, prosthetics, instruments, and devices for orthopedic surgeries, as well as products for wound care, skin care, and other surgical needs. Smith & Nephew focuses on providing innovative and high-quality products that help physicians achieve better outcomes for their patients. The company also invests in research and development of new technologies and products to continuously innovate and improve its portfolio. Smith & Nephew plc (SN) shares may be attractive to investors seeking investments in companies operating in the healthcare devices sector with a wide range of products and an emphasis on innovation and quality.

Sector

Healthcare

Industry

Medical - Devices

CEO

Deepak S. Nath

Employees

18,362

Headquarters

Watford

Valuation

Is today's price reasonable?

  • What to watch: The share price is above the Bulios Fair Price.

Growth and estimates

Is it growing, and what comes next?

  • What speaks for it: Earnings per share grew by 42% a year over the last 3 years.
  • What to watch: It missed profit estimates 6 times in the last 8 quarters.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What speaks for it: Out of every 100 USD of revenue, 14 USD is left as free cash.

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

  • What speaks for it: It bought back its own shares for $503.2M in the last fiscal year, 4.0% of its market value.

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy